Could a probiotic boost a cancer drug? new trial tests the combo
NCT ID NCT07578025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a probiotic capsule (MO-03) to the drug zanzalintinib can help treat metastatic kidney cancer that has worsened after immunotherapy. About 34 adults with advanced clear cell renal cell carcinoma will receive both treatments. The goal is to see if the combination shrinks tumors or slows cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanzalintinib (a targeted drug) and MO-03 (a probiotic capsule)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced kidney cancer that has stopped responding to immunotherapy.
- What could go wrong
- This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The combination may not work better than existing treatments, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer